These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 11956088

  • 1. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.
    Fu X, Zhang X.
    Cancer Res; 2002 Apr 15; 62(8):2306-12. PubMed ID: 11956088
    [Abstract] [Full Text] [Related]

  • 2. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
    Coukos G, Makrigiannakis A, Montas S, Kaiser LR, Toyozumi T, Benjamin I, Albelda SM, Rubin SC, Molnar-Kimber KL.
    Cancer Gene Ther; 2000 Feb 15; 7(2):275-83. PubMed ID: 10770637
    [Abstract] [Full Text] [Related]

  • 3. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms.
    Nakamori M, Fu X, Meng F, Jin A, Tao L, Bast RC, Zhang X.
    Clin Cancer Res; 2003 Jul 15; 9(7):2727-33. PubMed ID: 12855653
    [Abstract] [Full Text] [Related]

  • 4. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
    Wang J, Hu P, Zeng M, Rabkin SD, Liu R.
    Int J Oncol; 2012 Mar 15; 40(3):757-63. PubMed ID: 22108767
    [Abstract] [Full Text] [Related]

  • 5. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus.
    Fu X, Tao L, Cai R, Prigge J, Zhang X.
    Mol Ther; 2006 May 15; 13(5):882-90. PubMed ID: 16569513
    [Abstract] [Full Text] [Related]

  • 6. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10.
    Teshigahara O, Goshima F, Takao K, Kohno S, Kimata H, Nakao A, Nishiyama Y.
    J Surg Oncol; 2004 Jan 15; 85(1):42-7. PubMed ID: 14696086
    [Abstract] [Full Text] [Related]

  • 7. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
    Aghi M, Rabkin SD, Martuza RL.
    Cancer Res; 2007 Jan 15; 67(2):440-4. PubMed ID: 17234749
    [Abstract] [Full Text] [Related]

  • 8. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
    Lee CY, Rennie PS, Jia WW.
    Clin Cancer Res; 2009 Aug 15; 15(16):5126-35. PubMed ID: 19671871
    [Abstract] [Full Text] [Related]

  • 9. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma.
    Fu X, Nakamori M, Tao L, Amato R, Zhang X.
    Int J Oncol; 2007 Jun 15; 30(6):1561-7. PubMed ID: 17487379
    [Abstract] [Full Text] [Related]

  • 10. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, Hay C, Huang Y, Kaloss M, Marinov A, Phipps S, Pinkstaff A, Shirley P, Skripchenko Y, Stewart D, Forry-Schaudies S, Hallenbeck PL.
    Cancer Res; 2003 Apr 01; 63(7):1490-9. PubMed ID: 12670895
    [Abstract] [Full Text] [Related]

  • 11. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.
    Li H, Dutuor A, Fu X, Zhang X.
    J Gene Med; 2007 Mar 01; 9(3):161-9. PubMed ID: 17266169
    [Abstract] [Full Text] [Related]

  • 12. Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses.
    Mezhir JJ, Advani SJ, Smith KD, Darga TE, Poon AP, Schmidt H, Posner MC, Roizman B, Weichselbaum RR.
    Cancer Res; 2005 Oct 15; 65(20):9479-84. PubMed ID: 16230412
    [Abstract] [Full Text] [Related]

  • 13. Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics.
    Liu TC, Wakimoto H, Martuza RL, Rabkin SD.
    Clin Cancer Res; 2007 Oct 01; 13(19):5897-902. PubMed ID: 17908985
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice.
    Chung YS, Miyatake S, Miyamoto A, Miyamoto Y, Dohi T, Tanigawa N.
    Int J Oncol; 2006 Apr 01; 28(4):793-8. PubMed ID: 16525626
    [Abstract] [Full Text] [Related]

  • 16. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.
    Jarnagin WR, Zager JS, Hezel M, Stanziale SF, Adusumilli PS, Gonen M, Ebright MI, Culliford A, Gusani NJ, Fong Y.
    Cancer Gene Ther; 2006 Mar 01; 13(3):326-34. PubMed ID: 16138120
    [Abstract] [Full Text] [Related]

  • 17. Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases.
    Nomura N, Kasuya H, Watanabe I, Shikano T, Shirota T, Misawa M, Sugimoto H, Kanazumi N, Nomoto S, Takeda S, Nakao A.
    Cancer Chemother Pharmacol; 2009 Jan 01; 63(2):321-30. PubMed ID: 18575868
    [Abstract] [Full Text] [Related]

  • 18. A strict-late viral promoter is a strong tumor-specific promoter in the context of an oncolytic herpes simplex virus.
    Fu X, Meng F, Tao L, Jin A, Zhang X.
    Gene Ther; 2003 Aug 01; 10(17):1458-64. PubMed ID: 12900760
    [Abstract] [Full Text] [Related]

  • 19. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells.
    Taneja S, MacGregor J, Markus S, Ha S, Mohr I.
    Proc Natl Acad Sci U S A; 2001 Jul 17; 98(15):8804-8. PubMed ID: 11438715
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.